-
When, where, and how to target vascular inflammation in the post-CANTOS era?Maffia P, Guzik TJ. -
Comprehensive Investigation of Circulating Biomarkers and their Causal Role in Atherosclerosis-related Risk Factors and Clinical EventsD Zanetti , S Gustafsson, E Ingelsson et al.
-
Apolipoprotein A-V is a potential target for treating coronary artery disease: evidence from genetic and metabolomic analysesD Ibi, M Boot, MET Dollé et al.
-
Evolocumab for Early Reduction of LDL Cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS)KC Koskinas, S Windecker, G Pedrazzini et al.
-
Use of Risk Assessment Tools to Guide Decision-Making in the Primary Prevention of Atherosclerotic Cardiovascular Disease : A Special Report From the American Heart Association and American College of CardiologyDM Lloyd-Jones, LT Braun, CE Ndumele et al.
-
2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 DiabetesSR Das, BM Everett, KK Birtcher et al.
-
2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice GuidelinesGreenland P, American College of Cardiology Foundation; American Heart Association.
-
SR-B1 Drives Endothelial Cell LDL Transcytosis via DOCK4 to Promote AtherosclerosisLZ Huang, KL Chambliss, PW Shaul et al.
http://www.cbsmd.cn Contact us by cbs@cbsmd.cn
Copyright ⓒ CBSMD Nanjing China. All rights reserved.
